Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01109524 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT01109524 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 72 participants.
The verdict
NCT01109524, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if U.S. manufactured Cetuximab can be safely used for the treatment of Non-Small Cell Lung Cancer in combination with Cisplatin and Vinorelbine.
Interventions
- DRUG Cisplatin
- DRUG Cetuximab
- DRUG Vinorelbine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01109524
The ClinicalTrials.gov registry entry for NCT01109524 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT01109524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01109524 about?
NCT01109524 is a clinical study titled "Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer". The purpose of the study is to determine if U.S. manufactured Cetuximab can be safely used for the treatment of Non-Small Cell Lung Cancer in combination with Cisplatin and Vinorelbine.
What is the current status of trial NCT01109524?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2010-07. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01109524?
The interventions under investigation include: Cisplatin (DRUG), Cetuximab (DRUG), Vinorelbine (DRUG).
Who is sponsoring clinical trial NCT01109524?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.